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Naturally occurring FOXP3
1CD4
1 Treg have a crucial role in self-tolerance. The ability to
generate similar populations against alloantigens offers the possibility of preventing
transplant rejection without indeﬁnite global immunosuppression. Exposure of mice to
donor alloantigens combined with anti-CD4 antibody induces operational tolerance to
cardiac allografts, and generates Treg that prevent skin and islet allograft rejection in
adoptive transfer models. If protocols that generate Treg in vivo are to be developed in the
clinical setting it will be important to know the origin of the Treg population and the
mechanisms responsible for their generation. In this study, we demonstrate that graft-
protective Treg arise in vivo both from naturally occurring FOXP3
1CD4
1 Treg and from
non-regulatory FOXP3
CD4
1 cells. Importantly, tolerance induction also inhibits CD4
1
effector cell priming and T cells from tolerant mice have impaired effector function in vitro.
Thus, adaptive tolerance induction shapes the immune response to alloantigen by
converting potential effector cells into graft-protective Treg and by expanding alloreactive
naturally occurring Treg. In relation to clinical tolerance induction, the data indicate that
while the generation of alloreactive Treg may be critical for long-term allograft survival
without chronic immunosuppression, successful protocols will also require strategies that
target potential effector cells.
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Introduction
Current therapy for patients undergoing transplantation relies
upon indeﬁnite non-speciﬁc immunosuppression to prevent
rejection. Although modern immunosuppressive regimens have
dramatically improved early transplant outcomes [1], there has
been less impact on the rate of late graft loss [2]. Furthermore,
chronic immunosuppression exposes transplant recipients to drug
toxicity and an increased risk of malignancy [3] and infection [4].
A growing understanding of the intrinsic immunological mechan-
isms that control autoimmunity has led to the concept that
targeted immune-manipulation with agents such as anti-CD3 [5]
or anti-CD52 antibodies [6, 7] may promote regulation of donor-
directed immune responses, thus leading to improved graft
outcomes while preserving protective immunity.
Naturally occurring CD4
1 Treg that develop in the thymus under
the control of the transcription factor foxp3 [8–10] have a critical
role in peripheral immune homeostasis and lack of Treg, due to
congenital deﬁciency of foxp3 [11, 12] or selective depletion of
foxp3-expressing cells, [13, 14] results in fatal autoimmune disease.
In addition to controlling auto-reactive cells, Treg have also been
shown to suppress immune responses to foreign antigens in the
context of pregnancy [15], malignancy [16], infection [17] and
transplantation [18]. In several experimental models, Treg are
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tolerance [19–23] and the fact that regulation invariably depends on
TCR ligation provides the possibility of using speciﬁc antigens to
induce regulatory function in deﬁned situations. We have shown
that pre-treatment of naı ¨ve mice with a DST (donor-speciﬁc trans-
fusion) combined with anti-CD4 mAb generates CD25
1CD4
1 Tc e l l s
that prevent rejection of skin allografts by a deﬁned effector popu-
lation in lymphopenic adoptive transfer recipients [21, 24]. Impor-
tantly, this tolerance induction protocol also leads to indeﬁnite
cardiac allograft survival in immunologically intact recipients [25].
Successful translation of tolerance induction for potential
therapeutic use will depend on an understanding of how
alloantigen-reactive Treg are generated. In this study we provide
evidence that graft-protective Treg can arise in vivo both by
expansion of endogenous, naturally occurring FOXP3
1CD4
1
regulatory cells and by conversion of FOXP3
CD4
1 non-regula-
tory precursors. Moreover, we also demonstrate that tolerance
induction shapes the immune response to alloantigen by inhi-
biting the priming of IFN-g-secreting CD4
1 effector cells, result-
ing ultimately in impaired effector function.
Results
Tolerance induction with anti-CD41DST is dependent
on CD25
1 Treg
CBA (H2
k) mice pre-treated with DST and non-depleting anti-CD4
mAb (YTS177.9) on days 28 and 27 accept donor cardiac allografts
on day 0 without further immunotherapy [25]. To test the
hypothesis that heart allograft survival in immunocompetent
primary recipients is dependent on induced CD25
1CD4
1 Treg,
C B Am i c ew e r ep r e - t r e a t e dw i t ha n t i - C D 4 1H2
b DST on days 28 and
27, 7anti-CD25 mAb (PC61) on day 14 and transplanted with H2
b
cardiac allografts on day 0 (Fig. 1A). Administration of anti-CD25
mAb results in 490% depletion of CD25
1CD4
1 cells at the time of
transplantation (day 0, Fig. 1B) and at this time point is cleared
from the circulation (data not shown), thus depleting CD25
1 Treg
without impairing effector T-cell responses driven by the graft.
Tolerised mice accepted donor grafts indeﬁnitely (n56, MST
(median survival time)4100 days, Fig. 1C) but in contrast, mice
that also received depleting anti-CD25 mAb rejected their grafts
acutely (n56, MST 25 days) conﬁrming that CD25
1 Treg have a
non-redundant role in allograft acceptance in this model, a ﬁnding
supported by recent work demonstrating that ligation of gluco-
corticoid-induced TNFR-related protein (GITR) at the time of
transplantation also prevents graft acceptance [20].
Tolerant mice are enriched for graft-protective Treg
CD25
1CD4
1 cells from tolerant mice prevent donor skin graft
rejection mediated by naı ¨ve CD4
1 effector cells after adoptive
transfer into lymphopenic recipients [21, 24] but work by other
groups using similar adoptive transfer models has shown that naı ¨ve
CD25
1CD4
1 cells can also prevent rejection when transferred at a
high Treg:Teff ratio [26, 27]. However, the fact that naı ¨ve mice
reject cardiac allografts within 8 days [25] whereas mice tolerised by
the anti-CD41DST protocol accept their grafts long-term in a
manner dependent on Treg (Fig. 1) indicates a quantitative or
qualitative difference between tolerised Treg and their naı ¨ve
counterparts. This prompted us to compare directly the function of
CD25
1CD4
1 cells from tolerant and naı ¨ve unmanipulated mice in
t h es a m ea d o p t i v et r a n s f e rs y s t e m. Immunodeﬁcient CBA.rag (H2
k)
mice were reconstituted with naı ¨ve syngeneic CD25
CD4
1 cells as
an effector population together with CD25
1CD4
1 cells from tolerant
or unmanipulated CBA mice (Fig. 2A). After 1 day, full-thickness
H2
b skin grafts were transplanted. At a 1:1 Treg:Teff ratio, CD25
1
CD4
1 cells from either naı ¨ve or tolerised mice prevented rejection
(Fig. 2B). However, when the number of Treg was kept constant but
the number of effector T cells increased, a distinct difference
emerged in that CD25
1CD4
1 cells from anti-CD41DST-treated mice
were signiﬁcantly more effective than CD25
1CD4
1 cells from naı ¨ve
mice (Fig. 2C and D). To ask whether this effect was donor-speciﬁc,
experiments were performed using third party skin grafts from SJL
mice (H2
s) .A ss h o w ni nF i g .2 E ,t h e r ew as no signiﬁcant difference
in the ability of CD25
1CD4
1 cells from naı ¨ve or tolerised mice to
prevent SJL skin graft rejection. Thus, compared with unmanipu-
lated mice, the CD25
1CD4
1 T-cell pool from mice tolerised to donor
alloantigen is enriched signiﬁcantly for cells with the ability to
control the rejection of donor-strain allografts.
To ask whether this in vivo difference in Treg function could
be modelled in vitro, a proliferation suppression assay was
developed in which CFSE-labelled CD25
CD4
1 responder cells
from CBK mice (H2
k1transgenic K
b) were cultured with graded
numbers of CD25
1CD4
1 cells (Treg) from either naı ¨ve or anti-
CD41DST-treated CBA mice (H2
k) (Supporting Information
Fig. 1A). Irradiated splenocytes from CBAB10 F1 mice (H2
k1b)
were used as stimulators to provide direct stimulation via I-A
b
while also providing an exclusion gate in the proliferation
analysis. As shown in Supporting Information Fig. 1B, at a 1:1
ratio, both naı ¨ve and tolerised Treg suppressed efﬁciently the
proliferation of CD25
CD4
1 responder cells but unlike the in
vivo situation (Fig. 2), a titration of the Treg:responder ratio did
not reveal a difference between the two populations. Although its
simplicity makes the MLR an attractive assay with which to
examine in vivo responses, the overall clinical experience has
been that mixed lymphocyte responses do not provide a reliable
prediction or reﬂection of graft outcome [28] and, indeed, we
have previously noted a clear disparity between the in vivo and in
vitro suppressive capacity of CD25
1CD4
1 Treg [29]. These
observations highlight the limitations of the MLR to model in vivo
responses and stress the importance of functional in vivo models.
GITR
CD25
CD4
1 cells are depleted of naturally
occurring Treg
The observation that the precursor frequency of alloreactive cells
within naturally occurring Treg is similar to that in potential
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1CD4
1
cells can prevent allograft rejection at high Treg:Teff ratios
(Fig. 2) suggests that pre-existing, endogenous Treg appear to
make a signiﬁcant contribution to graft protection. However,
naı ¨ve CD4
1 T cells can undergo conversion into functional Treg
following antigen encounter in the peripheral immune system
[31, 32], indicating that conversion can also play a signiﬁcant
role. We have previously shown that when puriﬁed CD25
CD4
1
T cells are transferred into immunodeﬁcient mice, these can be
driven to become graft-protective Treg by the anti-CD41DST
tolerising protocol, suggesting that non-Treg precursors can be
converted to alloreactive Treg in vivo [24]. However, CD25 is an
imperfect marker for Treg and recent evidence has identiﬁed
the transcription factor FOXP3 as a master control gene for
naturally occurring Treg development, potentially providing
an improved marker for these cells in the mouse
[9, 10]. The limitations of CD25 for distinguishing Treg from
non-Treg is shown by the fact that some 20% of FOXP3
1 cells are
contained within the CD25
CD4
1 population (Fig. 3A). Further-
more, experiments using FOXP3
GFP-reporter mice have demon-
strated that in vitro, GFP
1CD25
CD4
1 cells suppress polyclonally
stimulated naı ¨ve CD4
1 T cells as efﬁciently as GFP
1CD25
1CD4
1
cells [33]. Thus, regulation observed in our previous experiments
[24] could have been due to expansion of FOXP3
1 cells contained
within the adoptively transferred CD25
CD4
1 population rather
than to de novo generation of Treg from non-regulatory
precursors.
We therefore sought a rigorous strategy to purify naı ¨ve
FOXP3
CD4
1 cells from WT mice in order to assess the impor-
tance of non-regulatory cell conversion in allograft tolerance.
Although B6 (H2
b) FOXP3
GFP-reporter were available to
us, we deliberately sought a strategy that would allow us to
isolate CD4
1 T cells devoid of nTreg from CBA (H2
k) mice to
allow direct comparisons to be made with the results of our
previous study [24]. To identify surrogate markers that might
allow ﬂow-puriﬁcation of FOXP3 negative cells, un-stimulated
CBA CD4
1 T cells were stained for FOXP3 and markers
associated with Treg phenotype and function, including
CD127, CD25, GITR, CTLA-4, CD62L, CD45RB and CD103. The
markers that allowed the most consistent discrimination between
FOXP3
1 and FOXP3
 cells were GITR, CD45RB and CD25
(Fig. 3B). The data were then re-analysed using pairs of markers
to calculate potential yields and purities from FACS sorting. The
highest predicted purity and yield of CD4
1FOXP3
 cells were
obtained using a combination of the markers CD4, CD25 and
GITR (Fig. 3C).
To validate this strategy for isolating viable cells devoid of
naturally occurring Treg, GITR
CD25
CD4
1 cells were sorted
from naı ¨ve CBA mice (Fig. 4A) and the resultant population
stained for intracellular FOXP3. Approximately 10% of freshly
isolated CD4
1 cells were FOXP3
1, but sorted GITR
CD25
CD4
1
cells consistently contained r0.5% FOXP3
1 cells (Fig. 4B and C).
Indeed, in our hands this strategy was as effective as sorting GFP

cells from FOXP3
GFP-reporter mice, suggesting the utility of this
approach in other non-transgenic mouse strains. As an additional
validation step, qRT-PCR was performed on sorted
GITR
CD25
CD4
1 cells to detect the presence of foxp3 mRNA.
CD4
1 cells from TCR-transgenic DKK.rag
/ mice, which do not
express FOXP3, were used as a negative control. Neither sorted
GITR
CD25
CD4
1 cells nor DKK.rag
/ cells generated a foxp3
0   d d− 7 2 d−28 d− 14
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Figure 1. Tolerance induction with anti-CD41DST is dependent on CD25
1 Treg. (A) CBA mice (H2
k) were pre-treated with 200mg of YTS177 (anti-
CD4 mAb) i.v. on days 28 and 27 together with 250mL whole H2
b blood (DST) on day 27. On day 14, mice in the CD25 targeting group received 1mg of
PC61 (anti-CD25 mAb) i.v. On day 0, donor-type (H2
b) vascularised heterotopic cardiac allografts were transplanted. (B) Representative plots (gated
on viable lymphocytes) showing depletion of CD25
1 T cells. Figures show percentage of CD25
1CD4
1 cells in the region indicated (mean7SEM, n53
mice per time point). (C) Cardiac allograft survival for mice in (A).
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DKK.rag
/ cells spiked with 0.5% freshly isolated CD25
1CD4
1
cells. These data therefore validate this strategy for the isolation
of viable populations essentially devoid of naturally occurring
Treg. For convenience, this population will be referred to as
FOXP3
 cells.
Alloreactive Treg can develop from FOXP3
 cells in vivo
To ask whether a proven tolerance induction protocol can
generate functional Treg from non-regulatory precursors,
CBA.rag mice (H2
k) were reconstituted with 110
6 sorted naı ¨ve
CBA FOXP3
 cells on day 35 (Fig. 5A). Anti-CD4 mAb was
administered i.v. on days 28 and 27 and 250mL whole H2
b blood
on day 27. On day 1, reconstituted mice additionally received
110
5 naı ¨ve syngeneic CD25
CD4
1 T cells to provide effectors
(sufﬁcient to reject a skin graft in CBA.rag mice, [24]) that had
not been exposed to the tolerance induction protocol, making it
possible to examine the effects of tolerance induction on Treg
generation independently of effects on alloreactive effector cells.
Thus, in this system, survival of a full-thickness H2
b skin allograft
transplanted on day 0 would depend on conversion of FOXP3

precursors into Treg. Control mice received naı ¨ve CD25
 cells
p=0.285
p=0.026
p=0 016
p=0.482
p=0.016
p
A
BC
DE
Figure 2. Tolerant mice are enriched for graft-protective Treg. (A) T- and B–cell-deﬁcient CBA.rag
/ mice (H2
k) were reconstituted with CD25

CD4
1 cells (Teff) puriﬁed from un-manipulated CBA mice and CD25
1CD4
1 cells (Treg) puriﬁed from either anti-CD4 1 H2
b DST treated or naı ¨ve un-
manipulated mice on day 1. On day 0, H2
b (donor) or H2
s (third party) skin allografts were transplanted. Data are from four independent
experiments. Survival was compared using the Log-rank test. (B) Donor graft survival after reconstitution with 110
5 Treg1110
5 Teff. (C) Donor
graft survival after reconstitution with 110
5 Treg1210
5 Teff. (D) Donor graft survival after reconstitution with 110
5 Treg1410
5 Teff.
(E) Third-party graft survival after reconstitution with 110
5 Treg1210
5 Teff.
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(Fig. 5A).
As shown in Fig. 5B, adoptive transfer control and anti-CD4
control mice rejected their skin allografts acutely (MST 19 days,
n56 and 19 days n54, respectively). In contrast, the majority of
mice in the tolerance induction group accepted their grafts long
term (MST4100 days, n58) with no signs of graft necrosis
(Fig. 5C). Thus, Treg with the capacity to prevent skin allograft
rejection can be converted from FOXP3
 precursors, implying
that naturally occurring Treg are not required for tolerance
induction in all situations.
To test the hypothesis that tolerance induction induces FOXP3
expression in non-regulatory cells, further cohorts of CBA.rag
/
mice (n53–4 per group) were reconstituted with 110
6
FOXP3
 cells as above, with or without tolerance induction
(Fig. 6A). On day 0, spleens were harvested and FOXP3 expres-
sion analysed by FACS. FOXP3
1 cells were readily detected in
both tolerised mice and controls (Fig. 6B), and unexpectedly
there was no signiﬁcant difference in the absolute number of
FOXP3
1 T cells between the two groups (Fig. 6C), indicating that
homeostatic proliferation of FOXP3
 cells is sufﬁcient to drive
FOXP3 expression, consistent with other recent reports [34, 35].
Critically, however, only Treg generated following tolerance
induction were capable of preventing graft rejection (Fig. 5).
These data highlight an important functional distinction between
Treg generated in the presence or absence of tolerogenic
therapy, and again show the limitations of phenotypic analysis
for inferring Treg function, particularly in lymphopenic
recipients.
To look for evidence of conversion in immunocompetent reci-
pients where homeostatic proliferation should not be a
confounding factor, 310
6 FACS sorted CD45.2
1GFP
CD4
1 cells
from H2
b FOXP3
GFP-reporter mice were adoptively transferred into
congenic CD45.1
1 H2
b recipients, and these mice then received
the tolerising anti-CD4/DST protocol (Fig. 7A). The purity of the
sorted input GFP
 population was 499% (Fig. 7B). Control
mice received anti-CD4 mAb alone, DST alone or adoptive transfer
only. On day 0, spleens were harvested and analysed by FACS.
Transferred cells were readily identiﬁed as indicated by the
analysis gate (Fig. 7C). As shown in Fig. 7D, the absolute number
of CD45.2
1GFP
1 cells was 47-fold higher in the anti-CD41DST
group (1.570.810
3) compared to the control groups (all
o0.210
3), demonstrating that phenotypic conversion of
FOXP3
 to FOXP3
1 cells can occur in the presence of a full
repertoire of CD4
1 cells.
Taken together, these data indicate that tolerance induction
can drive the direct conversion of FOXP3
 precursors into
FOXP3
1 Treg with the capacity to prevent allograft rejection
and imply that successful tolerance induction can both
increase the proportion of functional alloreactive Treg and by
conversion, lead to the depletion of potentially alloreactive
effector cells.
3
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Figure 3. Correlation of phenotypic markers with FOXP3 expression. Splenocytes from naı ¨ve CBA mice were stained for CD4, cell surface markers
and FOXP3. Histograms are gated on live CD4
1 cells, and are representative of three independent experiments. (A) Expression of CD25 and FOXP3
in gated viable CD4
1 cells. (B) Markers that correlated with FOXP3 expression. Figures indicate median ﬂuorescence intensities for FOXP3
 and
FOXP3
1 populations. (C) Predicted yield and purity of FOXP3 cells based on the pairs of markers shown.
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and in vitro cytotoxicity
Naı ¨ve CD4
1 T cells exhibit plasticity following activation and can
differentiate into diverse effector populations that in unmodiﬁed
transplant recipients lead to allograft rejection. We have obtained
evidence in two different systems that tolerance induction can result
in the emergence of regulatory cells from non-regulatory precursors,
but hitherto we have neglected the possible impact of tolerance
induction on potential effector cells within the T-cell compartment.
Previous work in human renal transplantation has shown a positive
correlation between increased frequencies of donor-reactive IFN-g-
secreting T cells and a higher incidence of acute rejection, chronic
allograft nephropathy and reduced 1-year allograft function
[36–38]. Therefore, IFN-g ELISpot analysis was used to examine
the impact of tolerance induction on alloreactive effector T-cell
responses. CBA mice were tolerised with the anti-CD41DST protocol
and controls received anti-CD4 mAb alone, DST alone or no
treatment (Fig. 8A). Spleens were harvested on day 0 and CD4
1
cells were challenged with T-cell-depleted H2
b donor-strain spleno-
c y t e si na nI F N - g ELISpot assay. The frequency of donor-reactive
CD4
1 cells in un-manipulated mice and anti-CD4-only controls was
not signiﬁcantly different from background (Fig. 8B). However,
mice that received DST alone showed clear evidence of priming,
with large numbers of donor-reactive IFN-g-secreting CD4
1 cells in
the spleen. In contrast, primed donor-reactive CD4
1 cells were
present at a four-fold lower frequency in tolerised mice compared to
DST only controls (7.671.010
3 versus 35.871.310
3,r e s p e c -
tively), indicating that in addition to promoting the development of
Treg, a further key effect of tolerance induction in this protocol is an
inhibition of alloreactive Th1 priming.
T-cell effector function was also evaluated in this system
using an in vitro cytotoxicity assay. To ask whether there is a
difference in the ability of T cells from tolerant mice to kill
donor strain targets, total T cells from un-manipulated or
tolerised mice were puriﬁed by negative selection and
re-stimulated with irradiated donor (H2
b) splenocytes
(Fig. 9A). On day 5, the T cells were re-isolated and incubated
with fresh donor (H2
b) splenocyte targets. After 6h, the absolute
number of live TCR-b
7AAD
Kb
1 target cells was determined by
FACS. As illustrated in Fig. 9B, T cells from tolerised mice had
signiﬁcantly impaired cytotoxicity compared to T cells from
unmanipulated mice, conﬁrming that tolerance induction has
multiple effects on the immune system, both generating allor-
eactive Treg and inhibiting the development or function of
cytotoxic T cells.
10.8% 0.4%
FACS
Sort by 
FACS
AB
CD
Figure 4. CD25
GITR
CD4
1 cells are essentially devoid of nTreg. (A) CBA splenocytes were stained for GITR, CD25 and CD4 and gated CD4
1 cells
with the lowest expression of CD25 and GITR were separated by FACS. (B) Input CD4
1 and sorted CD25
GITR
 cells were permeabilised and stained
for intracellular FOXP3 (gated on live CD4
1 cells). (C) Combined results from ﬁve independent FACS sorts (mean7SEM). (D) Sorted CD25
GITR

cells were analysed for foxp3 mRNA expression by qRT-PCR. Naı ¨ve CBA FACS separated CD25
1 cells were used as a positive control. DKK.rag TCRtg
CD4
1 cells were used as a negative control. In addition, DKK.rag CD4
1 cells were spiked with 0.5% naı ¨ve CBA CD25
1 cells. Results are normalised
against CD3 expression and are representative of three independent experiments.
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Several experimental approaches for the induction of donor-speciﬁc
transplantation tolerance have been validated in rodents and in
many of these models. CD25
1CD4
1 Treg play a critical role in graft
prolongation. As a result, many groups have focused their attention
on the in vivo or ex vivo generation of Treg, for manipulating
immune responses to an allograft. Adoptive transfer experiments in
the present study show that while CD25
1CD4
1 cells from un-
manipulated mice suppress allograft rejection at high Treg:Teff
ratios, these cells are signiﬁcantly less effective than CD25
1CD4
1
cells from tolerised mice. Importantly, the fact that graft-protective
Treg can be generated from CD4
1 precursors devoid of nTreg
underlines the importance of adaptive/induced Treg, but also
demonstrates that graft outcome is critically dependent on the
balance of graft-protective and graft-destructive T cells. Thus, the
data suggest that adaptive alloreactive Treg can arise by both
expansion and conversion, and that uncommitted cells can be
subverted to become regulatory cells. These data support the view
that peripheral T cells have a considerable capacity for plasticity in
terms of both loss and acquisition of speciﬁc functions. For example,
lineage-tracing experiments have shown that under inﬂammatory
conditions it is possible to ﬁnd in the pancreas of NOD mice a
population of ex-Treg that, though once positive for FOXP3 have
become FOXP3
 [39]. Similarly, it has recently been shown that
when transferred to T cell-deﬁcient hosts, FOXP3
1 T cells can
accumulate in Peyer’s patches of the gut and promote germinal
centre formation and B-cell activation. Signiﬁcantly, the majority of
T cells participating in these interactions lose FOXP3 expression
[40]. Although the cues that drive functional plasticity have not
been fully elucidated, it seems quite likely that inﬂammation and
the presence or absence of TGF-b play an important role [41]. This
seems to be particularly the case with respect to Th17 and induced
(adaptive) Treg where fate-switching seems to be dependent on the
local availability of TGF-b [42]. In this regard, it is interesting to
note that the anti-CD4/DST protocol delivers alloantigen via the
A
BC
Figure 5. Graft-protective Treg develop from FOXP3
 precursors in vivo. (A) CBA.rag mice (H2
k) were reconstituted with 110
6 sorted naı ¨ve CBA
(H2
k) FOXP3 cells on day 35; 200mg of YTS177 (anti-CD4 mAb) was administered i.v. on days 28 and 27, together with 250mL whole H2
b blood DSTon
day 27; 110
5 naı ¨ve CD25CD4
1 CBA (H2
k) effector cells were adoptively transferred on day 1. A full thickness H2
b skin allograft was transplanted
on day 0. Controls received anti-CD4 mAb without DST (anti-CD4 control) or adoptive transfer of cells alone (adoptive transfer control). Data are
from two independent experiments. (B) Skin allograft survival. Survival was compared using the Log-rank test. (C) Representative image of skin
graft at day 100 post-transplant.
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absence of overt inﬂammation. Thus, one simple possibility is that in
the absence of inﬂammation, plasticity can result in a non-Treg to
Treg conversion (Fig. 5 and 7), while in the presence of
inﬂammation, the opposite occurs. A simple distinction in outcome
based on the presence or absence of inﬂammation would have clear
physiological beneﬁts in the context of wider immunity by
maintaining peripheral regulation of responses to self but also
allowing the rapid elaboration of protective immunity following
infection where the presence of pathogens is invariably accompa-
nied by pro-inﬂammatory stimuli [43]. In this regard it is interesting
to note that in an analogous mouse tolerance induction model,
while pre-treatment with an anti-CD154/DST protocol leads to
long-term cardiac allograft survival, the addition of TLR9 ligation by
co-delivery of exogenous CpG results in acute rejection [44]. Thus,
the inﬂammatory context in which alloantigen is ﬁrst encountered
appears to have a signiﬁcant impact on the eventual immunological
outcome.
An additional aspect raised by the current study is that
although much of the evidence for T-cell plasticity has been
obtained by adoptive transfer of deﬁned populations into
lymphopenic or T-cell-depleted hosts, the data in Fig. 7 demon-
strate that non-Treg to Treg plasticity can be detected in immu-
nocompetent hosts. This appears to be an important observation
with respect to transplantation because it implies that it may be
possible to convert naı ¨ve alloreactive CD4
1 T cells into graft-
protective Treg in clinical transplant recipients without the need
for large-scale T-cell depletion.
Several publications support the observation that uncommitted
non-Treg can undergo peripheral conversion into cells that are
phenotypically and functionally indistinguishable from naturally
occurring Treg [31, 32, 45–47]. However, a recent study from
A
BC
Figure 6. FOXP3 analysis fails to reﬂect Treg generation from non-Treg precursors. (A) CBA.rag mice (H2
k) were reconstituted with 110
6 sorted
CBA (H2
k) FOXP3
 cells on day 35. The anti-CD41DST group received 200mg of YTS177 (anti-CD4) i.v. on days 28 and 27 together with 250mL whole
H2
b blood (DST) on day 27. Controls received adoptive transfer of cells alone. On day 0, spleens were harvested and FOXP3 expression analysed by
FACS. Representative data are shown from two independent experiments. (B) Proportion of TCR-b
1CD4
1 cells expressing FOXP3. (C) Absolute
number of FOXP3
1 T cells per spleen (mean7SD). Statistical analysis using the t test.
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compatibility antigen-mismatched mouse transplantation model
[48]. In this system, T-cell-deﬁcient BALB/c mice (H2
d)r e c o n -
stituted with syngeneic T cells prior to treatment with anti-CD4 mAb
(YTS177.9) plus DBA/2 DST accept DBA/2 (H2
d) skin allografts
long term. However, the same tolerance protocol was ineffective
w h e nt h em i c ew e r er e c o n s t i t u t e dw i t hG I T R
CD4
1 T cells rather
than total T cells, implying that input Treg are necessary for toler-
ance induction. The predominant pathway of allorecognition
through which graft-protective Treg are generated following toler-
ance induction is unclear but one possible explanation for the
contradiction between the data presented in Fig. 5 (MHC mismatch)
and those reported by Nagahama et al. is that conversion of non-
Treg precursors during tolerance induction occurs predominantly
within the direct rather than the indirect alloreactive T-cell pool.
A l t h o u g ht h e r ei se v i d e n c et h a tC D 8
1 T cells can be regulated by
CD4
1 adaptive Treg [49], it is likely that to achieve operational
tolerance in the wider setting, additional strategies will be required to
control CD8 responses, particularly those of CD8 memory cells [50].
In this study we demonstrate that total T cells from tolerised mice kill
donor-strain cells less efﬁciently than cells from un-manipulated
mice, raising the possibility that in addition to generating CD4
1 Treg,
tolerance induction in this system leads to the functional deletion of
alloreactive cytotoxic CD8
1 cells. Indeed, a previous study of toler-
ance induction using anti-CD154 mAb1DST provided clear evidence
for such a deletion [51]. Further support for this possibility is
provided by the ﬁnding that co-stimulation blockade was signiﬁ-
cantly less effective at prolonging allograft survival in mice where
T-cell resistance to activation-induced cell death was induced by BCL-
XL expression, implying that in some situations, deletion of effector
Tc e l l sc a nb ea ni m p o r t a n tc o m p o n ent of tolerance induction [52].
Combining tolerogenic therapy with T-cell depletion has been
suggested previously as a method of improving the ratio of graft-
destructive and graft-protective T cells [52, 53] but large-scale T-cell
depletion places patients at increased risk of infection and post-
transplant lymphoproliferative disease [54].
Our data demonstrate that alloantigen-dependent tolerance
induction has multiple effects on the recipient immune system,
and suggest that in the quest for clinical transplantation toler-
ance, attention should be focused on developing protocols that
not only generate graft-protective Treg but also target potential
effector cells. Given the low abundance of nTreg, the possibility
of generating graft protective Treg in vivo from the much larger
pool of alloreactive non-regulatory T cells is very attractive for
the induction of tolerance in the clinic.
Materials and methods
Animals
CBA.Ca (CBA, H2
k), C57BL/6 (B6, H2
b), C57BL/10 (B10, H2
b)a n d
CBA.rag1
/ (H2
k,k i n d l yp r o v i d e db yD .K i o u s s i s ,N I M R ,L o n d o n ,
UK) were housed in the BMSU, John Radcliffe Hospital. All
procedures complied with the UK Animals (Scientiﬁc Procedures)
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Figure 7. Treg develop from FOXP3
 precursors in immunocompetent mice. (A) 310
6 GFP
CD4
1CD45.2
1 T cells puriﬁed from FOXP3-GFP reporter
mice by ﬂow cytometry were adoptively transferred into congenic CD45.1
1 B6 mice on day 29. Recipient mice received 200mg anti-CD4 mAb
(YTS177) on days 28 and 27 with 250mLD B A 2( H 2
d) blood transfusion (DST) on day 27. Control mice received anti-CD4 mAb alone, DST alone or
adoptive transfer of GFP
CD4
1CD45.2
1 T cells only. On day 0, spleens were harvested and the number of GFP
1CD4
1CD45.2
1 T cells determined by
FACS. (B) Flow cytometry of sorted GFP
CD4
1CD45.2
1 T cells before injection. (C) Analysis gate for adoptively transferred CD45.2
1 T cells on day 0.
(D) Absolute numbers of FOXP3
GFP
1CD4
1CD45.2
1 T cells (mean7SEM, n53 mice per group).
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b,C D 4 5 . 2 )a n dD B A / 2( H 2
d)m i c e
were from the Jackson Laboratory, FOXP3
GFP-reporter mice (H2
b,
CD45.1) mice are as described previously [55].
Antibodies
The hybridomas YTS169 (anti-CD8) and YTS177.9 (anti-CD4)
were kindly provided by Prof. H. Waldmann (Sir William Dunn
School of Pathology, Oxford). The hybridomas TIB120 (anti-MHC
class II) and PC61 (anti-CD25) were from the ATCC. Conjugated
antibodies were from eBioscience (DTA-1, anti-GITR; PC61.5,
anti-CD25; H57-597, anti-TCR-b; FJK-16s, anti-FOXP3; GK1.5,
anti-CD4) or BD Pharmingen (AF6-88.5, anti-K
b).
Tolerance induction protocol
Mice received 200mg of anti-CD4 mAb (YTS177.9) i.v. on days 28
and 27 and a DST (250mL of whole donor-strain blood) i.v. on
day 27.
Skin transplantation
Full-thickness tail skin allografts were transplanted onto recipient
graft beds. Rejection was deﬁned as complete graft necrosis.
Survival was compared using the Log-rank test.
Heart transplantation
Heterotopic cardiac transplants were performed essentially as
described previously [56]. Rejection was deﬁned as lack of
palpable cardiac contraction and conﬁrmed by laparotomy.
Cell puriﬁcation
T cells were puriﬁed by magnetic separation as described
previously [21] or by ﬂow cytometry (BD FACSAria).
IFN-c ELISpot assay
Ninety-six-well MultiScreen plates (Millipore) were coated with
capture mAb (AN18, Mabtech). Responder and stimulator cells
were incubated for 14h followed by washing. Detection
mAb (biotinylated R4-6A2, Mabtech) was added, incubated for
A
B
Figure 8. Tolerance induction inhibits CD4
1 effector cell priming.
(A) CBA mice (H2
k) were pre-treated with 200mg of YTS177 (anti-CD4)
i.v. on days 28 and 27 together with 250mL whole H2
b blood (DST) on
day 27. Control mice received anti-CD4 alone, DST alone or no pre-
treatment. CD4
1 cells were puriﬁed from spleens harvested on day 0
and stimulated with H2
b1 splenocytes in an IFN-g ELISpot.
(B) Absolute number of donor-reactive IFN-g-producing CD4
1 cells
per spleen – pooled cells from four to ﬁve mice per group, representa-
tive of two independent experiments. Representative ELISpot well
images are shown. Statistical analysis using the t test.
A
B
Figure 9. Tolerance induction ameliorates in vitro cytotoxicity. (A) Total
T cells from unmanipulated or anti-CD41DST-treated mice were
stimulated in vitro for 5 days with irradiated H2
b splenocytes and then
h a r v e s t e d( e f f e c t o r s )a n dc u l t u r e df o r6hw i t hH 2
b1 splenocytes (target).
The absolute number of live 7AAD
K
b1 target cells was determined by
FACS. (B) Percentage killing (normalised to negative control). Data indicate
the mean7SD of triplicate tubes and are representative of four
independent experiments each using three to four mice per group.
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Alkaline phosphatase (Mabtech,) was added for 1h. Plates were
washed and developing substrate (Mabtech) was added. Spots
were enumerated with an AID ViruSpot plate reader and
ViruSpot 3.3 software (Autoimmun Diagnostika GmbH,
Germany).
In vitro cytotoxicity assay
T cells from naı ¨ve or tolerised mice were stimulated with
irradiated donor splenocytes. Graded numbers of T cells from
ﬁve day 1 cultures were incubated with (H2
b) targets for 6h. The
cells were stained with 7AAD, anti-TCR-b and anti-K
b antibodies.
7AAD
TCR-b
K
b1 targets were enumerated by FACS.
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